Osmosis Investment Management UK Ltd bought a new position in shares of Merck KGaA (OTCMKTS:MKGAF – Free Report) during the second quarter, HoldingsChannel.com reports. The firm bought 39,005 shares of the company’s stock, valued at approximately $5,012,000.
Other institutional investors also recently bought and sold shares of the company. Frazier Financial Advisors LLC purchased a new position in shares of Merck KGaA during the 2nd quarter worth $25,000. Rakuten Securities Inc. purchased a new stake in shares of Merck KGaA in the second quarter valued at $27,000. Solstein Capital LLC purchased a new stake in shares of Merck KGaA in the second quarter valued at $33,000. Burk Holdings LLC acquired a new position in Merck KGaA in the second quarter valued at $39,000. Finally, Bard Associates Inc. acquired a new position in Merck KGaA in the second quarter valued at $60,000. 0.10% of the stock is currently owned by institutional investors and hedge funds.
Merck KGaA Stock Performance
OTCMKTS MKGAF opened at $163.21 on Monday. The business’s 50-day moving average price is $162.62 and its 200 day moving average price is $148.44. The company has a current ratio of 1.31, a quick ratio of 0.84 and a debt-to-equity ratio of 0.27. Merck KGaA has a twelve month low of $116.68 and a twelve month high of $175.56. The company has a market capitalization of $21.09 billion, a PE ratio of 24.92 and a beta of 0.96.
Merck KGaA Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Featured Stories
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding MKGAF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck KGaA (OTCMKTS:MKGAF – Free Report).
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
